BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24800919)

  • 1. A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients - results of a randomized clinical trial.
    Hanff LM; Mathot RA; Smeets O; Postma DJ; Ramnarain S; Vermes A; Pieters R; Zwaan CM
    Int J Clin Pharmacol Ther; 2014 Aug; 52(8):653-62. PubMed ID: 24800919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
    Erb N; Harms DO; Janka-Schaub G
    Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
    Larsen RH; Hjalgrim LL; Grell K; Kristensen K; Pedersen LG; Brünner ED; Als-Nielsen B; Schmiegelow K; Nersting J
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):25-32. PubMed ID: 32519032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
    Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
    J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
    Tolar J; Bostrom BC; La MK; Sather HN
    Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
    Lennard L; Lewis IJ; Michelagnoli M; Lilleyman JS
    Med Pediatr Oncol; 1997 Oct; 29(4):252-5. PubMed ID: 9251729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.
    Wojtuszkiewicz A; Barcelos A; Dubbelman B; De Abreu R; Brouwer C; Bökkerink JP; de Haas V; de Groot-Kruseman H; Jansen G; Kaspers GL; Cloos J; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):422-33. PubMed ID: 24940700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
    Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism.
    Brackett J; Schafer ES; Leung DH; Bernhardt MB
    Pediatr Blood Cancer; 2014 Jun; 61(6):1114-7. PubMed ID: 24376133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.
    Bhatia S; Landier W; Hageman L; Chen Y; Kim H; Sun CL; Kornegay N; Evans WE; Angiolillo AL; Bostrom B; Casillas J; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Wong FL; Relling MV
    JAMA Oncol; 2015 Jun; 1(3):287-95. PubMed ID: 26181173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics.
    Berkovitch M; Matsui D; Zipursky A; Blanchette VS; Verjee Z; Giesbrecht E; Saunders EF; Evans WE; Koren G
    Med Pediatr Oncol; 1996 Feb; 26(2):85-9. PubMed ID: 8531858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between fasting hypoglycemia and methylated mercaptopurine metabolites in children with acute lymphoblastic leukemia.
    Melachuri S; Gandrud L; Bostrom B
    Pediatr Blood Cancer; 2014 Jun; 61(6):1003-6. PubMed ID: 24415675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
    Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children.
    Tiphaine Ade B; Hjalgrim LL; Nersting J; Breitkreutz J; Nelken B; Schrappe M; Stanulla M; Thomas C; Bertrand Y; Leverger G; Baruchel A; Schmiegelow K; Jacqz-Aigrain E
    Eur J Pharm Sci; 2016 Feb; 83():1-7. PubMed ID: 26657824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia.
    Bostrom B; Erdmann G
    Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):80-6. PubMed ID: 8447563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia.
    Tolbert JA; Bai S; Abdel-Rahman SM; August KJ; Weir SJ; Kearns GL; Neville KA
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28295989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia.
    Schmiegelow K; Bruunshuus I
    Cancer Chemother Pharmacol; 1990; 26(4):288-92. PubMed ID: 2369793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence study followed by model-informed dose optimization of a powder for oral suspension of 6-mercaptopurine.
    Arun B; Joshi M; Kakkar AK; Madki S; Ivaturi V; Chinnaswamy G; Banavali S; Gota V
    Pediatr Blood Cancer; 2024 Mar; 71(3):e30813. PubMed ID: 38110844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.